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In 1974, a group of visionary lung cancer investigators decided the need to form an association, which had the primary goal of facilitating research and clinical trials in 
lung cancer. After some years with encouraging treatment results of malignant lympho-
mas (particularly, Hodgkin’s disease) and certain forms of leukemia, the time came to 
focus on solid tumors. Systematic clinical trials in patients with solid tumors were in its 
beginning, and the lung cancer community consisting of a multidisciplinary group of 
investigators saw the need for collaborations and meetings to discuss new developments 
in cancer therapy, which could be applicable to lung cancer. At the first meeting at Airlie 
House in Virginia (April of 1974), a formal association—the International Association 
for the Study of Lung Cancer (IASLC)—was founded. The group established bylaws 
and an organizational infrastructure, which could facilitate work toward the mission. 
Although the World Conferences held every third year was the main meeting event, 
which gathered investigators from the different parts of the world, small workshops 
focusing on specific themes, e.g., biology of small cell lung cancer, multimodality treat-
ment of lung cancer, treatment of non–small-cell lung cancer, were held more frequently 
and were the vehicle to bring scientists and science together. The group of investiga-
tors saw a need for establishing a focused lung cancer journal to encourage and gather 
lung cancer-oriented scientific articles, and also the organization had a need for report-
ing the results from the different meetings. The first IASLC journal “Lung Cancer” 
was established after a few years with an “IASLC Newsletter.” Many scientific supple-
ments to “Lung Cancer” were published over the years addressing multiple themes. 
The IASLC journal “Lung Cancer” later turned into our current journal, Journal of 
Thoracic Oncology (JTO), which for many years was led by the first Chief Editor James 
Jett, who more recently was followed by the current Chief Editor Alex Adjei. All the 
workshops and the World Conferences certainly facilitated scientific collaborations, 
and facilitated also a specific “IASLC Culture” on the same time. Collaborations were 
established, and also friendships developed across geographical borders and specialty 
borders. Committees within IASLC were established with the Pathology Committee as 
the first one to be instrumental in the development of the World Health Organization’s 
international classification of lung tumors.
As the organization grew, there was a need for establishing an IASLC Headquarters 
and having an executive director. The first headquarters was localized in Copenhagen, 
Denmark, under the leadership of Prof. Heine Hoi Hansen. The IASLC continued to grow 
under the leadership of Dr. Paul A. Bunn Jr. as the executive director and several distin-
guished presidents.
During the 40 years, the IASLC has continuously promoted science and educa-
tion in lung cancer and most recently also in other thoracic malignancies. Notable are 
the organization’s contribution to standardize the histopathological classification of 
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malignant thoracic tumors by providing expertise and core 
committee for the World Health Organization’s classifica-
tion,1 and its contribution for a standardized, internationally 
recognized staging system.2,3 The pathology and the staging 
classifications from IASLC have been the backbone and ref-
erence for numerous scientific achievements both in basic 
science and clinical science, and the IASLC publications 
are significant contributions that are widely cited in the sci-
entific literature. Also through its smaller and larger meet-
ings IASLC has facilitated collaborations, which has led to 
scientific achievements within all aspects of thoracic oncol-
ogy.4,5 Most recently, the IASLC also developed guidelines 
for molecular testing and personalized therapy,6 which has 
been a model for similar guidelines in many countries. It is 
a great pleasure for IASLC to present in our journal, JTO, a 
series of articles describing more focused scientific achieve-
ments made over the 40 years, in which it has been directly 
or indirectly involved. The first article in this “Anniversary 
Series” of articles is published in the current issue of JTO by 
Dr. Novello et al7 and describes developments in early-stage 
non–small-cell lung cancer.
With contributions from our current leaders in the field, 
the development in our understanding of biology and improved 
clinical management of patients with lung cancer and other 
thoracic malignancies over the 40 years are described, and it 
is our hope that this will be to inspiration for new generation 
investigators to continue this development, which in the future 
will give a long-awaited hope for many desperate patients with 
lung cancer to turn lung cancer into a preventable, potential, 
curable “chronic disease.”
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